Rao M. Adibhatla’s Research Laboratory

 

Principal Investigator

          Rao M Adibhatla, Ph. D.

Personnel

        James F. Hatcher, B. S.

 

 
 

100_2272

Rao M. Adibhatla, Ph. D

Research Professor

Adibhatla’s CV

 

Address:

H4-330; Clinical Science Ctr.,

600 Highland Avenue

Dept. of Neurological Surgery

Univ. of Wisconsin-Madison

WI 53792-3232

Phone: (608) 263-1791

Fax: (608) 263-6901

VA lab:(608) 256-1901 X17809

adibhatl@neurosurg.wisc.edu

http://www.neurosurg.wisc.edu/images/adibhatla_lab_personnel_307_200.jpg

 

100_0112

James F. Hatcher, BS

Associate Researcher

Phone: 608-265-1101 hatcher@neurosurg.wisc.edu

 

 

 

 

 

 

 

 

NTP_Course_675 Lipids in Brain injury and disease

List 1     List of papers for student presentation

List 2     General references pertinent to course

Course Format

Sept 2, 2009 Lecture 1 (2 hrs Introduction, lipids in CNS injury and disorders); list of papers will be provided to make selection for final paper presentation

Sept 2, 2009 Lecture 2 (2 hrs Lipid Synthesis)

Sept 9, 2009 Lecture 3-4, (2 hrs Lipid hydrolysis, Lipid analysis, Brain cells, Arachidonic acid metabolism and lipid peroxidation)

Sept 16, 2009 Lecture 5-6, (Atherosclerosis, Plaque, Stroke Part I, Stroke neuroprotection and CDP choline) (1hr and stroke video) Student presentation schedule, selection of papers

Sept 23, 2009 Lecture 7-8, (Liposomes, clinical trials Stroke Part II) (Stroke Part IV) (Lipid in cell cycle)

Sept 30, 2009 Lecture 9-10, (Huntington and Parkinson)

Oct 7, 2009 Lecture 11-12 (Multiples sclerosis-EAE; Lysosomal disorders/Niemann-Pick/Peroxisomes/Zellweger

Oct 14, 2009 Lecture 13-14, (Traumatic brain injury, Spinal cord injury)

Oct 21, 2009 Lecture 15-16, (Epilepsy, bipolar disorders, Schizophrenia)

Oct 28, 2009 Lecture 17-18, (Topics that have not been covered)

Nov 4, 2009 Lecture 19 (Luigi Puglielli guest lecture; Instructor 1 hr Alzheimer’s disease and lipid connection)

Nov 11, 2009 Lectures 14 and 15, (Course evaluation; Guest lecture summary/250 words due)

TEST

Nov 18 2009 1—3 students paper presentation 35 min (20-25min + 5-10 min discussion)

Nov 25, 2009 4—6 students paper presentation 35 min (20-25min + 5-10 min discussion)

Dec 2, 2009, 7—9 students paper presentation 35 min (20-25min + 5-10 min discussion)

Dec 9, 2009 10-12 students paper presentation 35 min (20-25min + 5-10 min discussion)

Dec 16, 2009 13—16 students paper presentation 35 min (20-25min + 5-10 min discussion)

Final reports due (4 page, ~10 ref topic of choice)

COURSE EVALUATION FORM (for students)

 

Helpful Reviews (provided to the students)

Antiox Redox Signal (2009)

BMB reports 2008

Subcell. Biochem 2008

Front. Biosci. 2007

Future Lipidology 2007

Free Rad. Biol. Med 2006

Am. Assn. Pharmaceutical Scientist J 2006

Brain Res. 2005

 

Papers for presentation (presenter’s last and first name_date_author)

Fallace_Kathe_8Oct2008_Stack.pdf

Algiers_Tim_22Oct2008_Fergani.pdf

Gadow_Brett_22Oct2008_Djebaili.pdf

Elliott_Shaina_29Oct2008_Ehehalt.pdf

Guglielmetti_Caroline_5Nov2008_sahlin.pdf

Supplemental material

Lois_Kathrynn_5Nov2008_Kalyvas.pdf

Neuroscience 500 NTP Undergraduate Stroke talk (PowerPoint presentation)

Research Interests

Project 1

            Route of administration is critical.

Up-date on CDP-choline clinical trials

Project 2

Project 3

Funding

Invited Talks

Professional Services

AD-hoc reviewer

Neuroscience 625 course: Brain Cultures: Laboratory course:

Use of HPLC and GC in Neuroscience Research (PowerPoint presentation)

APCAS 2007

Delhi IIT 2007

NBRC 2007

Publications

Cytokines, lipid metabolism & stroke

CDP-choline & stroke

Polyamines & stroke

Other Publications

Adibhatla’s CV

PUBLICATIONS

·         70 papers in peer reviewed national and international journals.

·         73 presentations at various national and international meetings.

Adibhatla RM and Hatcher JF. (2006) Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med. 40:376-87. Elsevier publisher announced Adibhatla and Hatcher’ s article received the “Free Radical Biology & Medicine Top most cited papers 2005 - 2007 Award”.

 

Research Interests

 

Project 1

Cytidine-5’-Diphosphocholine (CDP–Choline or Citicoline) in Stroke and other CNS Disorders

CDP-choline improved the outcome of patients in phase III clinical trials of stroke. It was shown to have beneficial effects in a number of CNS injury models. AlText Box: though experimental evidence is limited, the therapeutic action of CDP-choline is thought to be due to stimulation of phosphatidylcholine (PC) synthesis in a damaged brain. Understanding the actions of CDP-choline could lead to development of more efficient treatment strategies for ischemia/reperfusion injury. Our studies of transient cerebral ischemia suggest that CDP-choline might enhance reconstruction (synthesis) of PC and sphingomyelin. CDP-choline could also act by inhibiting destructive processes (activation of phospholipases). The major mechanism of action of CDP-choline may be in modulating activation of phospholipase A2 (PLA2) (Scheme 1).

 

Integration of cytokine biology and lipid metabolism: CDP-choline beneficial effects could be attributed to interactions at TNF-α/IL-1 mediated events, differentially affecting phospholipases and CCT. This limits phospholipid hydrolysis and increases synthesis, thereby restoring PC and SM levels (Scheme. 2). Our recent studies also showed that PC loss is a cause rather than a result of cell death. Since all cells (neurons, astrocytes, and endothelial cells etc., called the ‘neurovascular unit’) contain PC as a membrane building block, CDP-choline protection may arise from stabilizing the ‘neurovascular unit’. These studies provide an integration of CDP-choline effects with cytokine biology and lipid metabolism in stroke.

Return to Top of page

CDP-CHOLINE IN STROKE CLINICAL TRIALS:

What factors might be critical?

•

Virtually no side effects and is well tolerated in stroke clinical trials.

•

Recent phase III stroke clinical studies by Davalos et al (Stroke 2002) showed that CDP-choline is effective in stroke

•

 

•

 

 

 

 

 

 

 

In light of these developments, future studies are warranted to further confirm the efficacy of CDP-choline for stroke treatment.

Route of administration is critical.

•         Route of administration: Oral (USA) vs i.v. (non-USA).

•         Brain uptake of CDP-choline, 0.5% (oral) vs 2% i.v.

•         Liposome encapsulated CDP-choline (brain uptake 23%) attenuated cerebral infarction better than other routes (ip and iv) of administration.

 

 

Up-date on CDP-choline Clinical Trials

·            IVAX, a Florida based company, in agreement with Grupo Ferrer (Barcelona, Spain) is filing for FDA approval of CDP-choline for acute stroke treatment.

·            Elder Pharmaceuticals (Mumbai, India) with Grupo Ferrer (Barcelona, Spain) launched CDP-choline (Somazina) phase III clinical trials for acute stroke treatment in India.

 

Other links to CDP- choline http://www.cdpcholine.com/

Return to Top of page

Project 2.

Phosphatidylcholine Homeostasis in Stroke

Significance: Tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1) are major pro-inflammatory cytokines and are rapidly up-regulated in brain after cerebral ischemia. Blockade of TNF-α by administration of TNF-α antibodies (TNF-α ab) or TNF-α binding protein attenuated ischemic brain injury in a number of studies. Transgenic mice deficient in both IL-1α and IL-1ß showed dramatic reduction in infarcts compared to wild-type mice. Similarly, treatment with IL-1 receptor antagonist (IL-1ra) reduced neuronal death in all forms of experimental cerebral ischemic injury.

TNF-α and IL-1 disrupt PC homeostasis (Scheme 3): In vitro studies have shown that PLA2 and PC-phospholipase C (PC-PLC) are induced by TNF-α and mediate their cytotoxicity. Activation of PLA2 by TNF-α/IL-1 may be mediated by increases in PLA2 activating protein (PLAP). PLAP in the rat brain has been characterized, but its role in cerebral ischemia has not been explored. PLA2 and PC-PLC hydrolyze PC, the major membrane phospholipid. PC loss is sufficient in itself to induce cell death. We have shown stimulation of PLA2, significant loss of phospholipids including PC  and significant decrease in cytidine triphosphate phosphocholine cytidylyltransferase (CCT) activity following transient brain ischemia.

PC synthesis: TNF-α and IL-1 inhibit CCT, the rate-limiting enzyme in PC synthesis. Thus these two proinflammatory cytokines may simultaneously stimulate PC hydrolysis and inhibit its synthesis (Scheme 2).

CDP-choline, formed by CCT, is the rate-limiting intermediate in the PC synthesis. Cholinephosphotransferase (CPT) catalyzes ultimate step of making PC from CDP-choline and 1,2-diacylglycerol. We have shown that CDP-choline treatment attenuated PLA2 activity, loss of CCT activity, hydroxyl radical (OH•) generation, lipid peroxidation, phospholipid hydrolysis and showed significant neuroprotection after transient cerebral ischemia.

Return to Top of page

Project 3

Polyamines in Stroke

Polyamines (putrescine, spermidine and spermine) are ubiquitous cellular components. The role of alterations in polyamine metabolism in neuronal degeneration after CNS injury remains an unresolved issue. Polyamines are important in the stabilization of cellular components such as cell membranes and chromatin structures; depletion of polyamines could lead to loss of cell integrity and cell death. Transient cerebral ischemia results in loss of spermine and spermidine. Our research seeks to determine whether normalization of the transient, ischemia–induced polyamine imbalance is neuroprotective. Spermine is considered to be an antioxidant and free radical scavenger, and restoring its levels may protect the brain from oxidative damage (either by scavenging hydroxyl radical or chelating Fe2+) following ischemia/reperfusion (Scheme 4).

Return to Top of page

 

Research Funding

 

•       American Heart Association Greater Midwest Affiliate, Principal Investigator (2006-08) for ‘Phosphatidylcholine metabolism and pro-inflammatory factors in stroke’ (Active).

•       University of Wisconsin Medical School Research Grant Principal Investigator (2008-2009) “Oxidized Phosphatidylcholine: A Marker for Neuroinflammation in Stroke” (Active).

•       UW-Graduate School Principal Investigator (2009-2010) for “Anti-inflammatory effects of phosphatidylcholine-

          phospholipase C (PC-PLC) inhibitor, D609 in stroke (Active)

•       Univ. of Wisconsin Graduate School, Univ. of Wisconsin Med. School, Dept. of Neurological Surgery Principal Investigator (2005-2008) Cytokines and lipid homeostasis in CNS injury (active)

•       NIH/NINDS/RO1 grant, Principal Investigator (2008-2012) for ‘Deregulated Lipid metabolism in Stroke’ (pending)

•       NIH/NINDS/R21 grant, Principal Investigator (2009-2011) for ‘Cell cycle regulation by lipid second messengers after stroke’ (pending)

•       American Heart Association Greater Midwest Affiliate, Principal Investigator (2008-10) ‘Cytokine modulation of phosphatidylcholine and sphingomyelin metabolism in stroke’ (pending).

•       NIH/NINDS RO1 National Institutes of Health/NINDS RO1 grant, Principal Investigator (2003-2008) ‘CDP-choline: Mechanisms in Cerebral Ischemia’ (Completed)

•       University of Wisconsin Medical School Research Grant Principal Investigator (2001-2002) for “Possible new mechanisms of CDP-choline neuroprotective in cerebral ischemia” (completed).

·       American Heart Association (Northland affiliate) (2003-04), ‘Polyamines in Cerebral Ischemia (PI: RJ Dempsey) (completed).

•       NIH/NINDS RO1, Co-PI “Ornithine Decarboxylase and Ischemic Brain Edema” RJ Dempsey, (PI) (completed).

•       NIH/NINDS Co-PI “Mechanisms of Brain Injury. Project 3. Acute Cellular Response to Brain Injury” AB Young, (PI) (completed).

Return to Top of page

 

INVITED TALKS

·            “CDP-Choline neuroprotective mechanisms in stroke” An update on Citicoline; Mini-symposium organized by Ferrer group, La Cantera Westin Resort, San Antonio, TX, July 2009.

·             “CDP-Choline neuroprotective mechanisms in stroke” Dept of Neurology, Leonard M. Miller School of Medicine at the University of Miami, March 2009.

·            “The Stroke Story of D609: Multifunctional or non specific?” Dept of Neurological Surgery Grand Rounds, Univ. of Wisconsin, March 2009.

·            Invited to participate in the "Citicoline-Update on its role in stroke recovery"  a symposium organized by leading neurologists Drs Marc Fisher; Antoni Davalos, Jeff Saver, Larry Wecsler and Steve Warach during International Stroke Conference in San Diego, Feb 19, 2009; and sponsored by Ferrer Grupo of Spain (the parent company of Citicoline).

·            “Altered phosphatidylcholine and sphingomyelin metabolism after stroke: Therapeutic strategies” Centre for Cellular and Molecular Biology, Hyderabad, India, December 2008.

·            “Altered phosphatidylcholine metabolism after stroke: Therapeutic strategies”. International Conference on Advances in Neuroscience, Cochin, Kerala, India, December 2008.

·            “Cell cycle and altered lipid metabolism: Anti-proliferative effects of phosphatidylcholine-phospholipase c (PC-PLC) inhibitor, D609 after stroke”. Soc. Neurosci. Nov 2008, Washington DC.

•       “Altered phosphatidylcholine metabolism after stroke: Therapeutic strategies”. Dept of Neurological Surgery Grand Rounds, Univ. of Wisconsin, April 2008.

•       ‘Primer on Brain disorders and diseases’ Guest of Honor lecture at VITHAM Institute of Technology, Vishakapatnam, India, April 2007.

•       ‘Lipid metabolism and cytokines in stroke’ National Brain Research Institute, Manesar, Guragon, New Delhi, India March 2007

•       ‘Mechanistic aspects of Citicoline actions in Stroke’ Asia Pacific Conference Against Stroke (APCAS 2007), Jointly organized by India, Pakistan, Bangladesh, Sri Lanka, New Delhi, March 2007.

•       ‘Primer on Brain disorders and diseases’ Indian Institute of Technology, New Delhi, India, March 2007.

•       ‘Lipid metabolism and cytokines in stroke’ Neuroscience lecture for undergraduates, UW Madison, WI, January, October 2007, Feb 2008

•       ‘Lipid metabolism and cytokines in stroke’ Neuroscience Training Program, UW Madison, WI, January 2007.

•       ‘Cytokine, lipid metabolism, and CDP-choline in stroke’ Alzheimer’s and neurodegenerative diseases seminar series, UW-Madison September 2006

•       ‘Loss of cellular phosphatidylcholine: a cause or a result of cell death?’ Alzheimer’s and neurodegenerative diseases seminar series, UW-Madison September 2006

CDP-choline mechanisms and Efficacy in Stroke

•       Department of Pathology, UW-Madison, May 2006

•       Grand Rounds, Dept of Neurological Surgery, UW-Madison, May 2005

•       Presented series of lectures to Neurologists/Neurosurgeons (at major Indian metropolitan cities) sponsored by Ferrer Grupo, Barcelona, Spain and Elder Pharmaceuticals, Mumbai, India to initiate CDP-choline (Somazina) phase III clinical trials of stroke in India, April 2005.

•       Molecular and Integrative Physiology, Kansas University Medical Center, Kansas City, KS, March 2005.

•       Brain and Cognitive Sciences & MIT clinical Research Center, Massachusetts Institute of Technology, Boston, MA, February 2005.

•       National Institute of Nutrition, Hyderabad, India, September 2004.

•       University of Hyderabad, Hyderabad, India, September 2004.

•       Neural Environment Cluster, Natl. Inst. Neurological Disorders and Stroke (NINDS, extramural); NIH, Bethesda, MD; September, 2003.

•       34th Am. Soc. Neurochemistry, New Port Beach, CA, May 3-7, 2003.

•       VA Medical Center, Minneapolis, MN, May 2003.

•       Cardiovascular Research Center; Univ. of Wisconsin, December 2002.

•       Natl. Inst. Neurological Disorders and Stroke (NINDS, intramural); NIH, Bethesda, MD; March, 2002.

•       Center for Cellular and Molecular Biology, Hyderabad, India, March, 2001.

ODC, Polyamines and CNS Injury

 

•    Gordon Conference on Polyamines, June 15-20, 2003, Connecticut College, London, CT.

•    Univ. of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, September 1996.

•    V A Medical Center, Minneapolis, Minnesota, July 1996.

•    Center for Cellular and Molecular Biology, Hyderabad, India, July 1996.

Return to Top of page

 

PROFESSIONAL SERVICES

•       Editorial board member for Neurochemical Research

•       Editorial board member for Current Neuropharmacology

•       Editorial board member for Annals of Neurosciences (Indian Academy of Neurosciences)

•       Grant Reviewer for the Austrian Genome Research Programme GEN-AU sponsored by The Austrian Federal Ministry for Education, Science and Culture.

•       Grant Reviewer for the Alzheimer’s Association.

•       Grant Reviewer for the Canadian ALS Association.

•       Grant Reviewer for the Unity through Knowledge_Croatia

•       Member of the National Brain Committee, American Heart Association Peer Review Study Group.

•       Abstract reviewer for The 22nd International Symposium on Cerebral Blood Flow, Metabolism, and Function & 7th International Conference on Quantification of Brain Function with PET; Amsterdam June 2005.

•       Abstract reviewer for The 23rd International Symposium on Cerebral Blood Flow, Metabolism, and Function & 8th International Conference on Quantification of Brain Function with PET; Tokyo, Japan, 2007.

 

Ad Hoc Reviewer for:

Atherosclerosis

Essays in Biochem.

Neurochem. Res. (Editorial board member)

Biochemical J.

Eur. J. Neurosci.

Neuroscience

Biochim. Biophys. Acta

Eur. J. Pharmacol.

Neuroscience Lett.

Brain Res.

Future Lipidology

Neurotoxic. Res.

Br. J. Pharmacol.

J Cereb Blood Flow Metab.

Neurosurgery

Cancer

J. Neurochem.

Prostaglandins, Leukotrienes and Essential Fatty Acids

Cell Biology International

J Neuroinflammation

Pediatric Res.

Cell. Mol. Neurobiol.

J. Neurosci. Res.

Pharmacol. Res.

Current Eye Res.

J. Neurosurgery

Stroke

Current Neuropharmacology (Editorial advisory board member)

Neurobiol. Disease

 

 

Return to Top of page

 

 

RECENT PUBLICATIONS

 

createpdficon_07 Adibhatla RM and Hatcher JF (2009) Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities. Antioxid. Redox Signal (in press)

createpdficon_07Adibhatla RM and Hatcher JF (2009) TNF-α: Neurotoxic or neuroprotective in stroke [electronic response to original Lambertsen et al., (2009) Microglia protect neurons against ischemia by synthesis of TNF. J. Neurosci. 29:1319-1330.

createpdficon_07Adibhatla RM (2009) Is the protection by tat-NR2B9c through partially reducing the ROS generation after stroke? [electronic response to original Girouard et al., (2009) NMDA receptor activation increases free radical production through nitric oxide and NOX2. J. Neurosci. 2009; 29: 2545-2552.

createpdficon_07Adibhatla RM and JF Hatcher: (2008) An odyssey of plaque to stroke: a lipid perspective (in press) www.athero.org

createpdficon_07Adibhatla RM and JF Hatcher: (2008) Phospholipase A2, reactive oxygen species, and lipid peroxidation in CNS injury and disorders. BMB reports 41(8): 560-567)

createpdficon_07ADIBHATLA RM and JF Hatcher (2008): Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of Stroke: Therapeutic Strategies. CNS & Neurological Disorders - Drug Targets 7: 243-253 (2008).

createpdficon_07ADIBHATLA RM and JF Hatcher (2008) Altered lipid metabolism in brain injury and disorders. Subcell. Biochem 49: 241-268.

createpdficon_07ADIBHATLA RM, Dempsey R and JF Hatcher (2008) Integration of cytokine biology and lipid metabolism in stroke. Front. Biosci. 13:1250-1270.

createpdficon_07ADIBHATLA RM and JF Hatcher (2007) Role of lipids in brain injury and diseases. Future Lipidology 2(4):403-422.

createpdficon_07EC Larsen, JF Hatcher and ADIBHATLA RM (2007) Effect of D609 on phospholipid metabolism and cell death during oxygen-glucose deprivation in PC12 cells. Neuroscience 146(3):945-961.

createpdficon_07ADIBHATLA RM and Hatcher (2007) Secretory phospholipase A2 IIA is up-regulated by TNF-α and interleukin 1α/ß after transient focal cerebral ischemia in rat. Brain Res. 1134:199-205.

createpdficon_07ADIBHATLA RM, Hatcher JF and Dempsey RJ (2006) Lipids and lipidomics in brain injury and diseases. Am. Assn. Pharmaceutical Scientist J 8(2):E314-E321.

createpdficon_07ADIBHATLA RM, Hatcher JF, Dempsey RJ (2003) Phospholipase A2, hydroxyl radicals and lipid peroxidation in transient cerebral ischemia. Antiox. Redox Signal. 5:647-654.

createpdficon_07Kirkland RA, ADIBHATLA RM, Hatcher JF, Franklin JL (2002): Loss of cardiolipin and mitochondria during programmed neuronal death: Evidence of a role for lipid peroxidation and autophagy. Neuroscience 115:587-602.

createpdficon_07ADIBHATLA, RM, Hatcher JF, MS Kindy, Dempsey RJ (1999) Arachidonic acid and leukotriene C4: Role in transient cerebral ischemia of gerbils. Neurochem. Res. 24:1225-1232.

createpdficon_07ADIBHATLA RM, Hatcher JF, Dempsey RJ (1999): Lipid metabolism in ischemic neuronal death. Recent Res. Developments in Neurochem. 2:533–549.

CDP-CHOLINE & STROKE

 

createpdficon_07ADIBHATLA RM, et al (2006) CDP-Choline significantly restores the phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP-phosphocholine cytidylyltransferase after stroke J. Biol. Chem.  281:6718-6725.

createpdficon_07ADIBHATLA RM and Hatcher JF (2006) Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Rad. Biol. Med. 40:376-387. Elsevier publisher announced Adibhatla and Hatcher’ s article received the “Free Radical Biology & Medicine Top most cited papers 2005 - 2007 Award”.

createpdficon_07ADIBHATLA RM, Hatcher JF, Tureyen K (2005) CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke. Brain Res. 1058:195-199.

createpdficon_07ADIBHATLA RM and Hatcher JF (2005) Cytidine-5’-diphosphocholine in stroke and other CNS disorders. Neurochem. Res. 30:15-23.

createpdficon_07ADIBHATLA RM, Hatcher JF, Dempsey RJ (2004) Cytidine-5’-diphosphocholine affects CTP:phosphocholine cytidylyltransferase and lyso-phosphatidylcholine after transient forebrain ischemia. J Neurosci. Res. 76:390-396.

createpdficon_07ADIBHATLA RM and Hatcher JF (2003) Citicoline attenuates phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci. Res. 73:308-315.

createpdficon_07ADIBHATLA RM, Hatcher JF (2002): Citicoline mechanisms and clinical efficacy in cerebral ischemia. J. Neurosci. Res. 70:133–139.

createpdficon_07ADIBHATLA RM, Hatcher JF, Dempsey RJ (2002): Citicoline: Neuroprotective mechanisms in cerebral ischemia. J. Neurochem. 80:12–23.

createpdficon_07ADIBHATLA RM, Hatcher JF, Dempsey RJ (2002): Citicoline: Mechanisms and stroke clinical trials. Neurology. http://www.neurology.org/cgi/eletters/ 57/9/1595.

createpdficon_07ADIBHATLA RM, Hatcher JF, Dempsey RJ (2001): Does CDP–choline modulate phospholipase activities after transient forebrain ischemia? Brain Res. 893:268–272.

createpdficon_07ADIBHATLA RM, Hatcher JF, Dempsey RJ (2001): Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke 32:2376–2381.

createpdficon_07ADIBHATLA RM, Hatcher JF, Dempsey RJ (2000): Lipid alterations in transient forebrain ischemia: Possible new mechanisms of CDP–choline neuroprotection. J. Neurochem. 75:2528–2535.

createpdficon_07ADIBHATLA RM, Hatcher JF, Dempsey RJ (1999): CDP-choline: Neuroprotection in transient cerebral ischemia of gerbils. J. Neurosci. Res. 58:697-705.

createpdficon_07ADIBHATLA RM, Hatcher JF, Sailor K, Dempsey RJ (2002): Polyamines and central nervous system injury: spermine and spermidine decrease following transient focal cerebral ischemia in spontaneously hypertensive rats. Brain Res. 938:81-86.

createpdficon_07ADIBHATLA RM, Hatcher JF, Dogan A, Dempsey RJ (2000): Elevated N1–acetylspermidine levels in gerbil and rat brains after CNS injury. J. Neurochem. 74:1106–1111.

createpdficon_07Dogan A, ADIBHATLA RM, Hatcher JF, Baskaya MK, Dempsey RJ (1999): Effects of MDL 72527, a specific inhibitor of polyamine oxidase, on brain edema, ischemic injury volume, and tissue polyamine levels in rats after temporary middle cerebral artery occlusion. J. Neurochem. 72:765–770.

createpdficon_07Dogan A, ADIBHATLA RM, Hatcher JF, Dempsey RJ (1999): The contribution of polyamine oxidase to brain injury after trauma. J. Neurosurg. 90:1078–1082.

createpdficon_07ADIBHATLA RM, Hatcher JF, Dempsey RJ (1999): Polyamine response to CNS injury: For better or for worse? Recent Res. Developments in Neurochem. 2:517–532.

createpdficon_07ADIBHATLA RM, Hatcher JF, Baskaya MK, Dempsey RJ (1998): Simultaneous assay of ornithine decarboxylase and polyamines after central nervous system injury in gerbil and rat. Neurosci. Lett. 256:65–68.

createpdficon_07Baskaya MK, ADIBHATLA RM, Dogan A, Dempsey RJ (1998): Increased ornithine decarboxylase activity and protein level in the cortex following traumatic brain injury in rats. Brain Res. 783:163–166.

createpdficon_07Baskaya MK, ADIBHATLA RM, Dogan A, Donaldson D, Gellin G, Dempsey RJ (1997): Regional brain polyamine levels in permanent focal cerebral ischemia. Brain Res. 744:302–308.

createpdficon_07ADIBHATLA RM, Baskaya MK, Maley ME, Kindy MS, Dempsey RJ (1997): Beneficial effects of S–adenosyl–L–methionine on blood–brain barrier breakdown and neuronal survival after transient cerebral ischemia in gerbils. Mol. Brain Res. 44:134–138.

createpdficon_07Baskaya MK, ADIBHATLA RM, Dogan A, Donaldson D, Dempsey RJ (1997): The biphasic opening of the blood–brain barrier in the cortex and hippocampus after traumatic brain injury in rats. Neurosci. Lett. 226:33–36.

createpdficon_07ADIBHATLA RM, Baskaya MK, Dempsey RJ (1995) Ornithine decarboxylase activity and edema formation in cerebral ischemia of the conscious gerbils. J Neurochem. 65:2639-2643.

Return to Top of page

createpdficon_07ADIBHATLA RM, Hatcher JF, Dempsey RJ (2000): Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil. Neurosci. Lett. 293:1–4.

createpdficon_07ADIBHATLA RM, Dempsey RJ (2001): Up–regulation of the peripheral–type benzodiazepine receptor expression and [3H]PK11195 binding in gerbil hippocampus after transient forebrain ischemia. J. Neurosci. Res. 64:493–500.

createpdficon_07ADIBHATLA RM, Dogan A, Hatcher JF, Dempsey RJ (1998): Fluorometric assay of nitrite and nitrate in brain tissue after traumatic brain injury and cerebral ischemia. Brain Res. 793:265–270.

 

Send Email to editor of this page

Last update: April 2009